GGrantIndex
← Leaderboards

John Jay Treanor

University Of Rochester

Google Scholar ↗PubMed ↗ORCID ↗
$65,365,577
Attributed
$65,365,577
Total exposure
27
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $9.4M · FY2005–21
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$62,022,723 · 26
CDC$3,342,854 · 1

By mechanism

N01$60,359,679 · 4
U18$3,342,854 · 1
M01$1,213,566 · 21
P01$449,478 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Influenza”

Research focus

InfluenzaImmune ResponseTransmission ProcessEvolutionImmuneVaccinationMolecularPandemic DiseaseAnimalsEnvironmental Risk FactorPathogenicityInfluenzavirusClinical ResearchHuman SubjectBasic ScienceDrug Screening /EvaluationHuman Therapy EvaluationDrug Adverse EffectMicroorganism Disease ChemotherapyAvian InfluenzaAntiviral AgentsInfluenza A VirusUniversal Influenza VaccineInfluenza Vaccines

Grant awards (72)

CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$174,459
N01 · FY2021 · AI · contact PI
CEIRS - SARS-CoV-2 RESEARCH$2,929,356
N01 · FY2020 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$2,420,833
N01 · FY2020 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA VACCINE RESEARCH$810,458
N01 · FY2020 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$456,982
N01 · FY2020 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH$1,994,885
N01 · FY2019 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH$1,107,422
N01 · FY2019 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$843,836
N01 · FY2019 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$843,836
N01 · FY2019 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$454,374
N01 · FY2019 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$454,374
N01 · FY2019 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$2,203,488
N01 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$1,611,898
N01 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$1,425,978
N01 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS$1,416,121
N01 · FY2018 · AI · contact PI
Centers of Excellence for Influenza Research and Surveillance$800,840
N01 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$629,468
N01 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS$419,542
N01 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$400,000
N01 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$314,784
N01 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$159,222
N01 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$2,789,358
N01 · FY2017 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$1,909,929
N01 · FY2017 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$2,948,804
N01 · FY2016 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$737,201
N01 · FY2016 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$3,966,682
N01 · FY2015 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$4,221,049
N01 · FY2014 · AI · contact PI
Centers of Excellence for Influenza Research and Surveillance$4,258,370
N01 · FY2013 · AI · contact PI
Centers of Excellence for Influenza Research and Surveillance$4,419,345
N01 · FY2012 · AI · contact PI
Centers of Excellence for Influenza Research and Surveillance$4,323,483
N01 · FY2011 · AI · contact PI
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA AND SURVEILLANCE$3,735,044
N01 · FY2010 · AI · contact PI
Estimates of Influenza Vaccine Effectiveness$1,100,000
U18 · FY2010 · IP · contact PI
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA AND SURVEILLANCE$4,678,258
N01 · FY2009 · AI · contact PI
Estimates of Influenza Vaccine Effectiveness$1,492,854
U18 · FY2009 · IP · contact PI
Estimates of Influenza Vaccine Effectiveness$750,000
U18 · FY2008 · IP · contact PI
EVALUATION OF CONTROL MEASURES AGAINST DISEASES OTHER THAN AIDS-266025-266025460$0
N01 · FY2006 · AI · contact PI
EVALUATION OF INTRAMUSCULAR MONOVALENT INFLUENZA A/H9N2 VACCINE IN ADULTS$151,042
M01 · FY2005 · RR
A PHASE 2 MULTICENTER RANDOMIZED TRIAL OF RPA-102 VACCINE IN HEALTHY VOLUNTEERS$133,818
M01 · FY2005 · RR
EVALUATE SAFETY &IMMUNOGENICITY OF VICAL PROPHYLACTIC ANTHRAX DNA IM VACCINE$89,300
M01 · FY2005 · RR
PSC01 TRIVALENT RECOMBINANT BACULOVIRUS-EXPRESSED HEMAGGLUTININ INFLUENZA VACE$40,278
M01 · FY2005 · RR
DIFFERENT DOSES OF IM TRIVALENT BACULOVIRUS-EXPRESSED INFLUENZA HA VACCINE$2,120
M01 · FY2005 · RR
Different Doses of IM Trivalent Baculovirus Influenza$326,490
M01 · FY2004 · RR
Study of gD-Alum/MPL HSV2 Vaccine in Preventionof Herpes$190,769
M01 · FY2004 · RR
Effects of Cytokine Polymorphisms on Influenza Response$151,856
M01 · FY2004 · RR
Study of DryVax Vaccine Against Smallpox$53,149
M01 · FY2004 · RR
Evaluation of Human Immune Response to Smallpox Vaccine$30,371
M01 · FY2004 · RR
NS1 PROTEIN IN INTERFERON INDUCTION &VIRUS REPLICATION$149,826
P01 · FY2002 · AI
PR, DBT, TO EVALUATE ACELLULAR PERTUSSIS VACCINE E IN ADOL &ADULT CH$0
M01 · FY2002 · RR
SAFETY/EFFICACY/PHARMACODYNAMIC--RWJ 270201 IN INFLUENZA$0
M01 · FY2002 · RR
PHARMCOKINETICS OF RWJ 270201 FOR EXPERIMENTAL INFLUENZA$0
M01 · FY2002 · RR
INFLUENZA THERAPY WITH NEURAMINIDASE INHIBITOR RO 64-079$0
M01 · FY2002 · RR
EVAL OF S&IMMUNO OF TRIVALENT INACTIVATED INFLUENZA VACCINE IN ADULTS$0
M01 · FY2002 · RR
SAFETY &IMMUNO OF INFLUENZA VIRUS VACCINE ADMIN TO HIV INFECTED &UN$0
M01 · FY2002 · RR
MYCOPLASMA PNEUMONIA &CHLAMYDIA AS ETIOLOGIC AGENTS OF COUGH IN$0
M01 · FY2002 · RR
PH II STUDY OF ANTIVIRAL EFFECT OF NEBULIZED ZANAMIVIR INFLUENZA VIRA$0
M01 · FY2002 · RR
PH I &II MC,R,DB,VC, STUDY OF S&TE OF TOPICAL R 848 GEL IN UVRI HERP$0
M01 · FY2002 · RR
NS1 PROTEIN IN INTERFERON INDUCTION &VIRUS REPLICATION$149,826
P01 · FY2001 · AI
EVALUATION OF INFECTIOUS CONTROL MEASURES$500,000
N01 · FY2000 · AI
NS1 PROTEIN IN INTERFERON INDUCTION &VIRUS REPLICATION$149,826
P01 · FY2000 · AI
DB, R, PC STUDY OF GS4104 IN TREATMENT OF INFLUENZA INFECTION$14,791
M01 · FY2000 · RR
INACTIVATED INFLUENZA VACCINE CONSISTING OF HEMAGGLUTININ$14,791
M01 · FY2000 · RR
PH II TRIAL OF S &I OF QUILIMMUNE P IN ELDERLY SUBJECTS$14,791
M01 · FY2000 · RR
PHARMCOKINETICS OF RWJ 270201 FOR EXPERIMENTAL INFLUENZA$0
M01 · FY2000 · RR
INFLUENZA THERAPY WITH NEURAMINIDASE INHIBITOR RO 64-079$0
M01 · FY2000 · RR
EVAL OF S&IMMUNO OF TRIVALENT INACTIVATED INFLUENZA VACCINE IN ADULTS$0
M01 · FY2000 · RR
SAFETY &IMMUNO OF INFLUENZA VIRUS VACCINE ADMIN TO HIV INFECTED &UN$0
M01 · FY2000 · RR
PR, DBT, TO EVALUATE ACELLULAR PERTUSSIS VACCINE E IN ADOL &ADULT CH$0
M01 · FY2000 · RR
MYCOPLASMA PNEUMONIA &CHLAMYDIA AS ETIOLOGIC AGENTS OF COUGH IN$0
M01 · FY2000 · RR
PH II STUDY OF ANTIVIRAL EFFECT OF NEBULIZED ZANAMIVIR INFLUENZA VIRA$0
M01 · FY2000 · RR
PH I &II MC,R,DB,VC, STUDY OF S&TE OF TOPICAL R 848 GEL IN UVRI HERP$0
M01 · FY2000 · RR
EVALUATION OF INFECTIOUS CONTROL MEASURES$0
N01 · FY2000 · AI
SAFETY/EFFICACY/PHARMACODYNAMIC--RWJ 270201 IN INFLUENZA$0
M01 · FY2000 · RR